Magnesium GlycinatevsPEA (Palmitoylethanolamide)

Magnesium is required for over 300 enzymatic reactions including neurotransmitter synthesis (tyrosine hydroxylase, tryptophan hydroxylase), energy production (ATPases, kinases, glycolytic enzymes), and DNA repair (PARP, DNA polymerases). In the brain, magnesium blocks NMDA receptors at the voltage-dependent Mg2+ binding site within the channel pore (GluN1/GluN2 subunits), preventing excessive calcium influx and excitotoxicity — Mg2+ is displaced only upon depolarization and glycine/glutamate binding. The glycine component activates inhibitory glycine receptors (GlyR alpha1/alpha2) in the brainstem and spinal cord, and serves as an obligatory co-agonist at the GluN1 glycine site of NMDA receptors. Glycine also modulates NMDA receptor function. Together, magnesium and glycine produce calming effects through complementary inhibitory mechanisms: reduced glutamatergic excitability and enhanced inhibitory neurotransmission.

PEA activates PPAR-alpha (peroxisome proliferator-activated receptor alpha), a nuclear receptor that heterodimerizes with RXR and downregulates pro-inflammatory gene expression (NF-kB target genes, COX-2, iNOS, TNF-alpha). It has an 'entourage effect' on the endocannabinoid system — it inhibits the degradation of anandamide by fatty acid amide hydrolase (FAAH) through allosteric modulation or substrate competition, and upregulates CB2 receptor expression on immune cells. This provides anti-inflammatory and analgesic effects without directly activating CB1/CB2. PEA also activates GPR55 and GPR119. It inhibits mast cell degranulation (reducing histamine, tryptase, and cytokine release) and reduces microglial activation in the brain (inhibiting Iba1 expression and pro-inflammatory cytokine production). PEA may also modulate TRPV1.